Immatics (IMTX) Operating Income (2019 - 2025)
Immatics recorded quarterly Operating Income of -$45.3 million in Q4 2025, up 29.14% quarter-over-quarter from -$63.9 million in Q3 2025, and down 4790.35% year-over-year from $964941.6 in Q4 2024.
Immatics' Operating Income history runs 7 years deep, the most recent figure standing at -$45.3 million for Q4 2025.
- In Q4 2025, Operating Income fell 4790.35% year-over-year to -$45.3 million; the TTM figure through Dec 2025 stood at -$206.5 million (down 395.03% YoY), while the FY2025 annual figure was -$205.6 million, down 398.36% from the prior year.
- Operating Income came in at -$45.3 million for Q4 2025 at Immatics, up from -$63.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $76.9 million in Q1 2022 to a low of -$63.9 million in Q3 2025.
- A 5-year average of -$21.2 million and a median of -$27.6 million in 2021 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 367.34% in 2022 and sank 65048.52% in 2023, its largest moves.
- Immatics' Operating Income stood at -$18.4 million in 2021, then surged by 100.25% to $45911.1 in 2022, then tumbled by 65048.52% to -$29.8 million in 2023, then jumped by 103.24% to $964941.6 in 2024, then plunged by 4790.35% to -$45.3 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$45.3 million, -$63.9 million, and -$60.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -45.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -45.26 Mn |
| Sep 30, 2025 | -63.87 Mn |
| Jun 30, 2025 | -60.14 Mn |
| Mar 31, 2025 | -37.21 Mn |
| Dec 31, 2024 | 964,941.65 |
| Sep 30, 2024 | 564,484.82 |
| Jun 30, 2024 | -28.61 Mn |
| Mar 31, 2024 | -14.63 Mn |
| Dec 31, 2023 | -29.82 Mn |
| Sep 30, 2023 | -36.21 Mn |
| Jun 30, 2023 | -15.59 Mn |
| Mar 31, 2023 | -28.37 Mn |
| Dec 31, 2022 | 45,911.13 |
| Sep 30, 2022 | -22.11 Mn |
| Jun 30, 2022 | -17.77 Mn |
| Mar 31, 2022 | 76.87 Mn |
| Dec 31, 2021 | -18.37 Mn |
| Sep 30, 2021 | -27.12 Mn |
| Jun 30, 2021 | -28.18 Mn |
| Mar 31, 2021 | -28.75 Mn |
| Dec 31, 2020 | -23.88 Mn |
| Sep 30, 2020 | -21.96 Mn |
| Jun 30, 2020 | -21.59 Mn |
| Mar 31, 2020 | -12.45 Mn |
| Dec 31, 2019 | -13.59 Mn |
| Sep 30, 2019 | -8.63 Mn |
| Jun 30, 2019 | -7.12 Mn |